以人为中心的整合照护对慢性肾脏病的效果:随机对照试验的系统综述与荟萃分析
该系统综述与荟萃分析纳入14项随机对照试验共4693例慢性肾脏病患者,平均随访12个月,评估以人为中心的整合照护对CKD的效果。中等质量证据显示,该照护模式可能对全因死亡率(RR 0.86,95%CI 0.68-1.08)或健康相关生活质量(SMD 0.02,95%CI -0.05-0.10)无影响;对肾脏替代治疗、血肌酐和eGFR的效果很不确定。定量分析提示可能减少全因住院(RR 0.38,95%CI 0.15-0.95)并改善血压控制(RR 1.20,95%CI 1.00-1.44),但证据确定性很低。
要点
- 以人为中心的整合照护可能不改善全因死亡率和健康相关生活质量。
- 对肾脏替代治疗、血肌酐和eGFR的影响很不确定。
- 可能减少全因住院并改善血压控制,但证据确定性很低。
核心结论
- 以人为中心的整合照护可能对死亡率或生活质量影响很小。
- 对血肌酐、eGFR和肾脏替代治疗的效果不确定,但可能减少住院并改善血压控制。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和Cochrane Central Register of Controlled Trials(自建库至2016年4月)。
- 纳入以人为中心整合照护干预的随机对照试验,最低随访3个月。
- 共纳入14项研究,4693例参与者,平均随访12个月。
- 采用随机效应荟萃分析评估效果。
主要发现
- 中等质量证据显示,以人为中心的整合照护可能对全因死亡率无影响(RR 0.86;95%CI 0.68-1.08)。
- 对健康相关生活质量可能无影响(标准化均数差 0.02;95%CI -0.05-0.10)。
- 对肾脏替代治疗(RR 1.00;95%CI 0.65-1.55)、血肌酐(均数差 0.59 mg/dl;95%CI -0.38-0.36)和eGFR(均数差 1.51 ml/min per 1.73 m2;95%CI -3.25-6.27)的效果很不确定。
- 定量分析提示可能减少全因住院(RR 0.38;95%CI 0.15-0.95)并改善血压控制(RR 1.20;95%CI 1.00-1.44),但证据确定性很低。
临床怎么用
- 以人为中心的整合照护可能减少CKD患者住院并改善血压控制。
- 对死亡率和生活质量未见明确获益,对肾功能进展的影响不确定。
局限性
- 纳入研究数量有限(14项),部分结局证据质量中等或很低。
- 对肾脏替代治疗、血肌酐和eGFR的效果很不确定。
- 住院和血压控制获益的证据确定性很低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The effectiveness of person-centered integrated care strategies for CKD is uncertain. We conducted a systematic review and meta-analysis of randomized, controlled trials to assess the effect of person-centered integrated care for CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (from inception to April of 2016), and selected randomized, controlled trials of person-centered integrated care interventions with a minimum follow-up of 3 months. Random-effects meta-analysis was used to assess the effect of person-centered integrated care. RESULTS: We included 14 eligible studies covering 4693 participants with a mean follow-up of 12 months. In moderate quality evidence, person-centered integrated care probably had no effect on all-cause mortality (relative risk [RR], 0.86; 95% confidence interval [95% CI], 0.68 to 1.08) or health-related quality of life (standardized mean difference, 0.02; 95% CI, -0.05 to 0.10). The effects on renal replacement therapy (RRT) (RR, 1.00; 95% CI, 0.65 to 1.55), serum creatinine levels (mean difference, 0.59 mg/dl; 95% CI, -0.38 to 0.36), and eGFR (mean difference, 1.51 ml/min per 1.73 m2; 95% CI, -3.25 to 6.27) were very uncertain. Quantitative analysis suggested that person-centered integrated care interventions may reduce all-cause hospitalization (RR, 0.38; 95% CI, 0.15 to 0.95) and improve BP control (RR, 1.20; 95% CI, 1.00 to 1.44), although the certainty of the evidence was very low. CONCLUSIONS: Person-centered integrated care may have little effect on mortality or quality of life. The effects on serum creatinine, eGFR, and RRT are uncertain, although person-centered integrated care may lead to fewer hospitalizations and improved BP control.
引用
- Valentijn PP, Pereira FA, Ruospo M, et al. Person-Centered Integrated Care for Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin J Am Soc Nephrol. 2018. PMID: 29438975. doi:10.2215/CJN.09960917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。